Share Price
19.50 p
0 (0.00 %)
Market Cap
£16.18 m
Proactive Investors - Run By Investors For Investors


A pioneer of human disease models and an industry leading clinical development services business  with an analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick...

Market: LSE:HVO
52-week High/Low: 105.00p / 18.00p
Sector: Pharma & Biotech
Market Cap: £16.18 m
Website: hvivo.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of hVIVO PLC

hVIVO PLC Snapshot

Vision / Strategy

Our Vision and Values

To become the partner of choice for companies developing products in airways disease.


Our Mission

Overcome unmet medical need barriers by providing human models of disease which bridge the translation gap from animal to man, and which can illuminate the molecular and cellular causes of disease.


hVIVO: Better treatments, faster.

The demand for new treatments in the drive towards a healthier world is a pressing one. There is a real need to better understand the true causes of debilitating and life threatening conditions and identify the best way to alleviate or cure them.


Our Values: One team, Growth, Integrity, Innovation

One team:

We work as one high performing team, each playing to our best, committed to delivering shared goals with passion, energy and enthusiasm. Succeeding together is as important as succeeding individually. We celebrate success together.


We are committed to growing and developing our employees, professionally and personally, through our unique experiences in a scientifically, intellectually, pioneering environment. Our vision is inspiring, opening up unexplored opportunities and the ability to achieve.


We take personal ownership for our actions and always act in ways that build trust and respect with the people around us. We believe in clear, open and honest communication.


We are pioneering in our approach, working with level headedness and listening to others’ ideas. We are courageous in embracing new challenges and in our determination to do things differently and better. Our agility allows us to define and redefine our markets.

Human Challenge Study Services in Drug Development

With the evolution of increasingly more virulent viral diseases, increasing complexity of managing chronic diseases, and growing pressure to deliver safer, more effective treatments at a faster pace, current processes are no longer sufficient. You need to understand the disease progression and human response in more detail early to improve respiratory drug development time, costs and efficiency, including trial design, dosing regimens, and safety profiles.- to read more click here.



Other Services – Clinical Lab Testing and Target & Biomarker Discovery - to read more click here.

Directors of hVIVO plc

Dr Trevor Phillips, Executive Chairman
Dr Trevor Phillips became a Non-Executive Director of hVIVO plc in June 2017 and Executive Chairman in November 2017. Trevor has over thirty years of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focused on respiratory diseases. Subsequent to joining Vectura in 2010, Trevor played an integral leadership role in the company’s successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.

Prior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company, where he was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development, commercial product manufacturing and M&A activity. He led the merger of Critical Therapeutics with Cornerstone BioPharma Holdings. He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc).

Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986. He was awarded an MBA from Henley Management College in 1997.


Graham Edward Yeatman, Chief Financial & Business Officer
Graham joined hVIVO Services Limited (formerly Retroscreen Virology Limited) as Finance Director in May 2011 and became Finance Director of hVIVO plc (formerly Retroscreen Virology Group plc) in April 2012. Graham was promoted to Chief Financial and Business Officer in January 2015.

Graham has significant experience of building businesses for rapid growth and profitability. He is a Chartered Accountant and trained and worked with PricewaterhouseCoopers for thirteen years across its audit, tax, consultancy, business process reengineering and outsourcing divisions. In 2001 he joined buyingTeam Limited (subsequently renamed Proxima) as Finance & Operations Director and was influential in growing the business to become one of the UK’s leading purchasing services providers. In 2006 he joined Neuropharm Group plc as Chief Financial Officer. Graham has a First in Economics and Maths from Bristol University.


Jaime Ellertson, Non-Executive Director
Jaime Ellertson was appointed non-executive Chairman of Retroscreen Virology Group PLC in June 2014. (now hVIVO PLC)

Jaime Ellertson has a strong track record of leading fast growing, data and service driven companies through phases of rapid expansion, both in the private and public arena. Jaime is currently Chairman and Chief Executive Officer of Everbridge Inc., a provider of multi-dimensional critical communications solutions to leading Health Care, Corporate and Government organisations globally.

He lives in Massachusetts and is a citizen of the United States of America. Jaime previously served as the Chief Executive Officer, President and Director of Gomez Inc., a company specialising in monitoring and managing Web site data and Web application performance. During his tenure he led Gomez Inc. through an IPO registration that resulted in the successful sale of the company for $295M to Compuware Corporation (NASDAQ: CPWR). He served as Chief Executive Officer, President and Director of S1 Corporation Inc. (NASDAQ: SONE), a software provider to the financial services marketplace. Jaime also orchestrated the highly successful turnaround of Interleaf, Inc. (NASDAQ: LEAF), a provider of software tools for e-content management, culminating in its acquisition for $852M by BroadVision Inc in 2000.

Earlier in his career, Jaime founded several high growth software companies including Openware Technologies Inc., Document Automation Corporation and Purview Technologies Inc.. He has also served on the boards of a number of public and private US and UK based companies


Dr Trevor Nicholls, Non-Executive Director
Dr Trevor Nicholls became a non-executive director of the Company on 21 May 2014.

Trevor is a company director having over 30 years of building international businesses in the life science industry, with a strong focus on genomics and proteomics. In particular, he was previously Chairman of Oxford Nanopore Technologies Limited, is currently Chairman of Avacta Group plc and was the Chairman of Activiomics Limited prior to its acquisition by Retroscreen. Trevor is also Chief Executive Officer of CABI, a not-for-profit inter-governmental organisation owned by 46 member countries worldwide. Prior to his current role with CABI, he was Chief Commercial Officer for Affymetrix Inc with accountability for global operations, delivering $330 million revenue with 600 staff across 8 locations worldwide.

His technology knowledge and leadership will be invaluable as Retroscreen expands its bio-analytical activities.


Dr Mark Warne, Non-Executive Director
Mark Warne became a Non‑Executive Director of hVIVO in April 2016 and will act as Chairman of the Remuneration Committee.

He is currently Head of IP Group’s Healthcare division, which at the end of December 2015, had shareholdings in 31 companies valued at over £275 million. Mark also represents IP Group on the boards of a number of its portfolio companies, both quoted and private; notably Genomics plc, Cronin Group plc and Crysalin Limited.

Mark has been at IP Group since 2008 and has extensive experience in building world‑changing healthcare businesses as well as in managing transactions including portfolio company IPOs, financings and M&A. He joined IP Group from pre‑clinical drug discovery CRO, Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly known as Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.


James F. Winschel, Non-Executive Director
James F. Winschel became a non-executive director of the Company on 1 October 2014 and is Chairman of the Audit Committee.

Jim retired in June 2014 as Executive Vice President at PAREXEL International Corporation (“PAREXEL”), a US publicly-traded healthcare services company (NASDAQ: PRXL) with $1.9 billion in annual service revenue. He previously served as Senior Vice President and Chief Financial Officer of PAREXEL from 2000 to 2013, with responsibility for directing all financial activities, during a period when PAREXEL’s revenue grew by $1.5 billion, backlog increased by $4.5 billion and market capitalisation increased from $225 million to $2.7 billion.

Jim is currently a Director of Cambrex Corporation, a US company offering products, services and technologies to accelerate the development and commercialisation of small molecule therapeutics. Earlier in his career, Jim spent five years at BTM Capital Corporation, a Bank of Tokyo-Mitsubishi Ltd. subsidiary, initially as Executive Vice President and Chief Financial Officer for three years from 1995 before being promoted to President, U.B. Vehicle Leasing, Inc. through 2000. Prior to these roles, he was the Vice President – Finance, Physician Services Division at Caremark International, Inc. for two years from 1993 and spent the previous four years at Whirlpool Financial Corporation (WFC), both as the Vice President & Managing Director, Commercial Financing Division and prior to that as the Vice President and Chief Financial Officer. Jim worked for five years in various roles at General Electric Capital Corporation, in the Transportation and Industrial Financing Division and prior to that at General Electric Company for eleven years.

Significant Shareholders

The Company has been notified of or is aware of the following significant shareholders:




Invesco Limited



Woodford Investment Management Limited



IP2IPO Limited



IP Venture Fund



Lansdowne Partners (UK) LLP



The percentage of the Company’s issued share capital that is not in public hands is 68.1%.

There are no restrictions on the transfer of securities.

This page was last updated on: 25 June 2018

Main Switchboard: Our  number for colleagues and clients is
+44 (0) 20 7756 1300

Main London office and registered business address:
hVIVO Services Limited
Queen Mary BioEnterprises (QMB)




Ernst & Young LLP, Apex Plaza, Forbury Road, Reading, Berkshire, RG1 1YE


Nominated adviser and broker

Numis Securities Limited, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT



Pinsent Masons LLP, 30 Crown Place, London, EC2A 4ES



Equiniti, Aspect House, Spencer Road, Lancing, BN99 6DA


Registered office

Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX

Registered in England and Wales, Registered number 08008725

Columns Including HVO


Market Reports Including HVO

Video RSS



© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use